Pharmacyclics clinches $150 million up front from Janssen in blood cancer deal
This article was originally published in Scrip
Pharmacyclics has received $150 million up front under a development and commercialisation deal with Johnson & Johnson unit Janssen Biotech for a first-in-class oral candidate for haematological malignancies currently in Phase II trials.
You may also be interested in...
AbbVie/Pharmacyclics executives Danelle James and Mohamed Zaki, in an interview at ASH, discussed Imbruvica's worth in chemo-free settings and noted additional value that could be created with shorter durations of treatment in combination regimens.
From the latest COVID-19 advances to the emergence of game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.